Lexicon’s reliance on risk mitigation protocols for type 1 diabetes pursuit for Zynquista elicits mixed reactions

shutterstock_274849448
Efforts by Lexicon Pharmaceuticals to have Zynquista approved for type 1 diabetes has split experts on whether protocols to reduce the diabetic ketoacidosis (DKA) risk will be sufficient.